You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immune Checkpoint Inhibitor (ICI) therapy

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Rotterdam (Nutritional intervention, Immunotherapy)

Recruiting
  • Non-small Cell Lung Cancer
  • Rotterdam, Netherlands
    Erasmus MC
Jun 5, 2023

Adverse Events-related Healthcare Resource Utilization and Costs

Completed
  • Melanoma
  • East Hanover, New Jersey
    Novartis Pharmaceuticals
Jan 27, 2023

Prediction in Solid Tumors

Recruiting
  • Malignant Solid Neoplasm
  • Biospecimen Collection
  • Questionnaire Administration
  • Ames, Iowa
  • +5 more
Sep 7, 2022

Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer

Completed
  • Cancer Treated With Immune-checkpoint Inhibitors
  • Immune checkpoint inhibitor
  • Bordeaux, France
    Institut Bergonié, Comprehensive Cancer Center
Dec 6, 2021

Advanced Solid Tumor Trial (INCB099280)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
May 19, 2023

Melanoma Trial in Toulouse (Nivolumab+Ipilimumab in combination with Anti TNF-a Certolizumab, Nivolumab+Ipilimumab in

Active, not recruiting
  • Melanoma
  • Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
  • Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
  • Toulouse, France
    Institut Claudius Regaud IUCT-ONCOPOLE
Nov 18, 2022

Cancer, Immune-related Adverse Event, Cardiac Abnormalities, Variable Trial in Belgium (Cardiology consultation, Chest Computed

Recruiting
  • Cancer
  • +6 more
  • Cardiology consultation
  • +4 more
  • Deinze, East-Flanders, Belgium
  • +3 more
Jan 26, 2023

ICI-combined Strategies Presented With Promising Efficacy in

Completed
  • Non Small Cell Lung Cancer
  • immune checkpoint inhibitor-combined
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Nov 21, 2021

Gastrointestinal Cancer Trial in New York, Providence (Cobimetinib, Hydroxychloroquine, Atezolizumab)

Active, not recruiting
  • Gastrointestinal Cancer
  • New York, New York
  • +1 more
Nov 29, 2022

Immune Checkpoint Inhibitor, Lung Cancer, Liver Biomarkers Trial in Amiens (Blood sample)

Recruiting
  • Immune Checkpoint Inhibitor
  • +3 more
  • Blood sample
  • Amiens, France
    CHU Amiens
Dec 8, 2022

Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemo Effect Trial in Guangzhou (PD-1 Immune Checkpoint

Active, not recruiting
  • Recurrent Nasopharyngeal Carcinoma
  • +2 more
  • PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
  • Guangzhou, Guangdong, China
    Yanqun Xiang
Sep 5, 2022

Metastatic Melanoma, Advanced Melanoma Trial in San Francisco (XmAb22841, XmAb23104)

Not yet recruiting
  • Metastatic Melanoma
  • Advanced Melanoma
  • San Francisco, California
    University of California, San Francisco
Jan 13, 2023

Severe Checkpoint Inhibitor Pneumonitis Trial in Beijing (Corticosteroids, Corticosteroids and Ruxolitinib)

Recruiting
  • Severe Checkpoint Inhibitor Pneumonitis
  • Beijing, Beijing, China
    Department of Respiratory Medicine, Peking Union Medical College
Jun 12, 2023

Gut and Tumor Microbiome in Advanced ER-positive and

Not yet recruiting
  • Breast Cancer
  • Melanoma
  • Observation
  • (no location specified)
Nov 6, 2023

Pneumonitis Trial in Chongqing (single-cell sequencing)

Not yet recruiting
  • Pneumonitis
  • single-cell sequencing
  • Chongqing, Chongqing, China
    Xinqiao Hospital
Jul 12, 2022

Advanced Malignant Solid Tumor Trial in Huntersville (BNT314, Pembrolizumab)

Not yet recruiting
  • Advanced Malignant Solid Tumor
  • BNT314
  • Pembrolizumab
  • Huntersville, North Carolina
    Carolina BioOncology Institute, LLC
Nov 21, 2023

Liver Metastasis Colon Cancer Trial (IRE plus checkpoint inhibitor, IRE plus Checkpoint Inhibitor plus CpG-ODN)

Not yet recruiting
  • Liver Metastasis Colon Cancer
  • IRE plus checkpoint inhibitor
  • IRE plus Checkpoint Inhibitor plus CpG-ODN
  • (no location specified)
Sep 13, 2023

Fecal Microbiota Transplantation (FMT) Trial in New York (Fecal Microbiota Transplantation (FMT))

Recruiting
  • Fecal Microbiota Transplantation (FMT)
  • Fecal Microbiota Transplantation (FMT)
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 24, 2022

Adjuvant Immune Checkpoint Inhibitors in Postoperative

Recruiting
  • Hepatocellular Carcinoma
  • Immune Checkpoint Inhibitors Based Adjuvant therapy
  • Nanning, Guangxi, China
    Jian-Hong Zhong
Jan 18, 2023

Solid Tumor, Hematologic Malignancy Trial in Beijing (Eliglustat, Immune checkpoint inhibitor)

Recruiting
  • Solid Tumor
  • Hematologic Malignancy
  • Beijing, China
    Department of Biotherapeutic, Chinese PLA General Hospital
Apr 28, 2022

Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Malignant Solid Neoplasm
    • Alton, Illinois
    • +6 more
    May 18, 2022

    HBV Reactivation Between High HBV-DNA and Low HBV-DNA Loads

    Recruiting
    • Hepatocellular Carcinoma
    • ICI
    • Antiviral Prophylaxis
    • Guangzhou, Guangdong, China
    • +3 more
    Jan 4, 2022

    NSCLC Stage IV, Melanoma Stage IV, Unresectable Melanoma Trial in Montréal (Camu Camu Capsules (Camu Camu powder encapsulated

    Recruiting
    • NSCLC Stage IV
    • +3 more
    • Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI
    • Montréal, Quebec, Canada
      Centre hospitalier de l'Université de Montréal (CHUM)
    Jul 18, 2022

    Colitis, Diarrhea, Malignant Genitourinary System Tumor Trial in Houston (Fecal Microbiota Transplantation, Loperamide)

    Recruiting
    • Colitis
    • +8 more
    • Houston, Texas
      M D Anderson Cancer Center
    Oct 17, 2022

    NSCLC, Squamous Cell Carcinoma of the Head and Neck Trial in Lexington (Immune checkpoint inhibitor, Radiation Therapy)

    Recruiting
    • Non-small Cell Lung Cancer
    • Squamous Cell Carcinoma of the Head and Neck
    • Immune checkpoint inhibitor
    • Radiation Therapy
    • Lexington, Kentucky
      University of Kentucky Markey Cancer Center
    Nov 10, 2022